264 related articles for article (PubMed ID: 27888143)
21. Solid state properties and drug release behavior of co-amorphous indomethacin-arginine tablets coated with Kollicoat® Protect.
Petry I; Löbmann K; Grohganz H; Rades T; Leopold CS
Eur J Pharm Biopharm; 2017 Oct; 119():150-160. PubMed ID: 28602869
[TBL] [Abstract][Full Text] [Related]
22. In vitro and in vivo comparison between crystalline and co-amorphous salts of naproxen-arginine.
Kasten G; Lobo L; Dengale S; Grohganz H; Rades T; Löbmann K
Eur J Pharm Biopharm; 2018 Nov; 132():192-199. PubMed ID: 30266670
[TBL] [Abstract][Full Text] [Related]
23. Dissolution and precipitation behavior of ternary solid dispersions of ezetimibe in biorelevant media.
Alhayali A; Tavellin S; Velaga S
Drug Dev Ind Pharm; 2017 Jan; 43(1):79-88. PubMed ID: 27487184
[TBL] [Abstract][Full Text] [Related]
24. Raman and thermal analysis of indomethacin/PVP solid dispersion enteric microparticles.
Fini A; Cavallari C; Ospitali F
Eur J Pharm Biopharm; 2008 Sep; 70(1):409-20. PubMed ID: 18621516
[TBL] [Abstract][Full Text] [Related]
25. Amino acids as co-amorphous excipients for simvastatin and glibenclamide: physical properties and stability.
Laitinen R; Löbmann K; Grohganz H; Strachan C; Rades T
Mol Pharm; 2014 Jul; 11(7):2381-9. PubMed ID: 24852326
[TBL] [Abstract][Full Text] [Related]
26. Stabilization of low glass transition temperature indomethacin formulations: impact of polymer-type and its concentration.
Chokshi RJ; Shah NH; Sandhu HK; Malick AW; Zia H
J Pharm Sci; 2008 Jun; 97(6):2286-98. PubMed ID: 17879977
[TBL] [Abstract][Full Text] [Related]
27. Polymer incorporation method affects the physical stability of amorphous indomethacin in aqueous suspension.
Surwase SA; Itkonen L; Aaltonen J; Saville D; Rades T; Peltonen L; Strachan CJ
Eur J Pharm Biopharm; 2015 Oct; 96():32-43. PubMed ID: 26092472
[TBL] [Abstract][Full Text] [Related]
28. Thermoanalytical and Fourier transform infrared spectral curve-fitting techniques used to investigate the amorphous indomethacin formation and its physical stability in Indomethacin-Soluplus® solid dispersions.
Lin SY; Lin HL; Chi YT; Huang YT; Kao CY; Hsieh WH
Int J Pharm; 2015 Dec; 496(2):457-65. PubMed ID: 26481469
[TBL] [Abstract][Full Text] [Related]
29. Physicochemical properties of amorphous precipitates of cimetidine-indomethacin binary system.
Yamamura S; Gotoh H; Sakamoto Y; Momose Y
Eur J Pharm Biopharm; 2000 May; 49(3):259-65. PubMed ID: 10799818
[TBL] [Abstract][Full Text] [Related]
30. Preparation and recrystallization behavior of spray-dried co-amorphous naproxen-indomethacin.
Beyer A; Radi L; Grohganz H; Löbmann K; Rades T; Leopold CS
Eur J Pharm Biopharm; 2016 Jul; 104():72-81. PubMed ID: 27130786
[TBL] [Abstract][Full Text] [Related]
31. Influence of the cooling rate and the blend ratio on the physical stability of co-amorphous naproxen/indomethacin.
Beyer A; Grohganz H; Löbmann K; Rades T; Leopold CS
Eur J Pharm Biopharm; 2016 Dec; 109():140-148. PubMed ID: 27746228
[TBL] [Abstract][Full Text] [Related]
32. The formation and physical stability of two-phase solid dispersion systems of indomethacin in supercooled molten mixtures with different matrix formers.
Semjonov K; Kogermann K; Laidmäe I; Antikainen O; Strachan CJ; Ehlers H; Yliruusi J; Heinämäki J
Eur J Pharm Sci; 2017 Jan; 97():237-246. PubMed ID: 27890595
[TBL] [Abstract][Full Text] [Related]
33. Preparation and characterization of amorphous ciprofloxacin-amino acid salts.
Mesallati H; Conroy D; Hudson S; Tajber L
Eur J Pharm Biopharm; 2017 Dec; 121():73-89. PubMed ID: 28919470
[TBL] [Abstract][Full Text] [Related]
34. Impact of Eudragit EPO and hydroxypropyl methylcellulose on drug release rate, supersaturation, precipitation outcome and redissolution rate of indomethacin amorphous solid dispersions.
Xie T; Gao W; Taylor LS
Int J Pharm; 2017 Oct; 531(1):313-323. PubMed ID: 28844901
[TBL] [Abstract][Full Text] [Related]
35. Investigation of Ethylene Oxide-co-propylene Oxide for Dissolution Enhancement of Hot-Melt Extruded Solid Dispersions.
Hurley D; Potter CB; Walker GM; Higginbotham CL
J Pharm Sci; 2018 May; 107(5):1372-1382. PubMed ID: 29410037
[TBL] [Abstract][Full Text] [Related]
36. Preparation and structural characterization of amorphous spray-dried dispersions of tenoxicam with enhanced dissolution.
Patel JR; Carlton RA; Yuniatine F; Needham TE; Wu L; Vogt FG
J Pharm Sci; 2012 Feb; 101(2):641-63. PubMed ID: 22095696
[TBL] [Abstract][Full Text] [Related]
37. Preparation and Evaluation of Co-amorphous Formulations of Telmisartan-Amino Acids as a Potential Method for Solubility and Dissolution Enhancement.
Khanfar M; Al-Remawi M; Al-Akayleh F; Hmouze S
AAPS PharmSciTech; 2021 Mar; 22(3):112. PubMed ID: 33748914
[TBL] [Abstract][Full Text] [Related]
38. Co-former selection for co-amorphous drug-amino acid formulations.
Kasten G; Löbmann K; Grohganz H; Rades T
Int J Pharm; 2019 Feb; 557():366-373. PubMed ID: 30578980
[TBL] [Abstract][Full Text] [Related]
39. Biorelevant dissolution testing of a weak base: Interlaboratory reproducibility and investigation of parameters controlling in vitro precipitation.
Berben P; Ashworth L; Beato S; Bevernage J; Bruel JL; Butler J; Dressman J; Schäfer K; Hutchins P; Klumpp L; Mann J; Nicolai J; Ojala K; Patel S; Powell S; Rosenblatt K; Tomaszewska I; Williams J; Augustijns P
Eur J Pharm Biopharm; 2019 Jul; 140():141-148. PubMed ID: 31051249
[TBL] [Abstract][Full Text] [Related]
40. Indomethacin-omeprazole as therapeutic hybrids? Salt and co-amorphous systems enhancing physicochemical and pharmacological properties.
Nascimento ALCS; Martins ICB; Spósito L; Morais-Silva G; Duarte JL; Rades T; Chorilli M
Int J Pharm; 2024 Mar; 653():123857. PubMed ID: 38281693
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
